GH Research (GHRS) Current Assets (2021 - 2025)
GH Research's (GHRS) quarterly Current Assets came in at $286.0 million in Q4 2025, up 85.43% year-on-year from $154.2 million in Q4 2024, and down 2.99% quarter-over-quarter from $294.8 million in Q3 2025.
GH Research (GHRS) Current Assets (2021 - 2025) Analysis & Trends
GH Research's Current Assets history runs 5 years deep, the most recent figure standing at $286.0 million for Q4 2025.
- On a quarterly basis, Current Assets rose 85.43% year-over-year to $286.0 million in Q4 2025; TTM through Dec 2025 was $286.0 million, a 85.43% increase from a year earlier, with the FY2025 full-year figure at $286.0 million, up 85.43% from the prior year.
- Current Assets retreated to $286.0 million in Q4 2025 per GHRS's latest filing, from $294.8 million in the prior quarter.
- Across five years, Current Assets topped out at $294.8 million in Q3 2025 and bottomed at $152.9 million in Q2 2024.
- The 5-year median for Current Assets is $167.5 million (2022), against an average of $215.1 million.
- Across the five-year window, Current Assets slumped 39.77% in 2023 and surged 92.19% in 2025, its largest moves.
- Year by year, Current Assets stood at $166.0 million in 2021, then increased by 1.51% to $168.5 million in 2022, then declined by 2.64% to $164.1 million in 2023, then fell by 6.01% to $154.2 million in 2024, then surged by 85.43% to $286.0 million in 2025.
- Per Business Quant, the three latest GHRS Current Assets figures stand at $286.0 million (Q4 2025), $294.8 million (Q3 2025), and $293.9 million (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 289.93 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 73.04 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 6.60 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 35.73 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 11.73 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 18.21 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 521.86 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 8.07 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 1.97 Bn |
| 10 | GH Research | 1.69 Bn | 1.69 Bn | - | 285.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 285.98 Mn |
| Sep 30, 2025 | 294.79 Mn |
| Jun 30, 2025 | 293.88 Mn |
| Mar 31, 2025 | 294.67 Mn |
| Dec 31, 2024 | 154.23 Mn |
| Sep 30, 2024 | 154.95 Mn |
| Jun 30, 2024 | 152.91 Mn |
| Mar 31, 2024 | 160.48 Mn |
| Dec 31, 2023 | 164.09 Mn |
| Sep 30, 2023 | 164.04 Mn |
| Jun 30, 2023 | 166.40 Mn |
| Mar 31, 2023 | 164.72 Mn |
| Dec 31, 2022 | 168.54 Mn |
| Sep 30, 2022 | 260.04 Mn |
| Jun 30, 2022 | 266.23 Mn |
| Mar 31, 2022 | 273.46 Mn |
| Dec 31, 2021 | 166.03 Mn |
| Sep 30, 2021 | 285.56 Mn |